South Korea's NHIS has approved reimbursement for XPOVIO in combination with bortezomib and dexamethasone for multiple myeloma patients after one prior therapy, effective March 1, 2026.

Bracco Imaging launches AI-powered contrast enhancement software AiMIFY® in the European Union and announces a new partnership with Avicenna.AI for AI applications in CT imaging at ECR 2026.

Cynosure Lutronic announces regulatory approvals for its Clarity II dual-wavelength laser system in China and Japan, expanding its footprint in Asia's regulated aesthetic medical device markets.

ACCURIDS launches AI-enabled EMA PMS Compliance Solution to automate data alignment and ensure readiness for XEVMPD decommissioning and EMA Strategy 2028 ahead of the Medicines for Europe conference on February 26-27, 2026.

Vietnam's government has approved a comprehensive national strategy to transform its pharmaceutical sector into a $20 billion industry by 2045, emphasizing manufacturing, regulatory upgrades, and foreign partnerships.[3]

Antengene Corporation and Shanghai Junshi Biosciences have entered a clinical collaboration to evaluate ATG-037 combined with JS207 for solid tumor treatment in Mainland China.

The European Medicines Agency updated its records on February 25, 2026, regarding the Executive Steering Group meeting focused on addressing shortages and safety issues in medicinal products supply across Europe.

China's NMPA has expanded fast-track access for overseas drugs, streamlining regulatory approvals to accelerate market entry and foster global pharmaceutical collaborations.

Diamyd Medical has finalized the clinical database for the pre-specified interim efficacy analysis in its Phase 3 DIAGNODE-3 trial evaluating the Diamyd diabetes vaccine in recently diagnosed children and adolescents with Type 1 diabetes.

Hansoh Pharmaceutical Group achieves landmark EU regulatory approval for its third-generation EGFR-TKI drug Aumolertinib Mesylate Tablets, marking a key expansion in Europe's oncology market.